| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691) | Hutchmed | 2022-02-15 |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (NCT04840602) | National Cancer Institute (NCI) | 2022-01-05 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas (NCT04883437) | Emory University | 2021-09-03 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275) | National Cancer Institute (NCI) | 2021-05-20 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (NCT04279405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-06-15 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders (NCT03601819) | University of Michigan Rogel Cancer Center | 2019-05-15 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCT03884998) | City of Hope Medical Center | 2019-02-26 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT03410901) | Ronald Levy | 2018-04-09 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221) | University of Maryland, Baltimore | 2017-10-23 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL (NCT03019666) | Masonic Cancer Center, University of Minnesota | 2017-10-18 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Study of VTD in Waldenstrom's Macroglobulinemia (NCT03335098) | Seoul National University Hospital | 2016-11-21 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922) | University of Washington | 2016-05-19 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma (NCT01209871) | M.D. Anderson Cancer Center | 2015-02-26 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas (NCT01314014) | University of Rochester | 2011-05-01 |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (NCT01282424) | Gilead Sciences | 2011-03-18 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) (NCT00923507) | National Heart, Lung, and Blood Institute (NHLBI) | 2008-05-29 |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (NCT00801281) | Polish Lymphoma Research Group | 2007-02-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia (NCT00142129) | Dana-Farber Cancer Institute | 2003-12-01 |
| Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia (NCT00142116) | Steven P. Treon, MD, PhD | 2003-05-01 |
| Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia (NCT00142181) | Dana-Farber Cancer Institute | 2003-03-01 |
| Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia (NCT00566332) | French Study Group on Chronic Lymphoid Leukemia | 2001-06-01 |